Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer : a meta-analysis

Tools
- Tools
+ Tools

Giacchetti, S., Dugue, P. A., Innominato, P. F., Bjarnason, G. A., Focan, C., Garufi, C., Tumolo, S., Coudert, B., Iacobelli, S., Smaaland, R., Tampellini, M., Adam, R., Moreau, T. and Lévi, Francis A. (2012) Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer : a meta-analysis. Annals of Oncology, Volume 23 (Number 12). pp. 3110-3116. doi:10.1093/annonc/mds148 ISSN 0923-7534.

Research output not available from this repository.

Request-a-Copy directly from author or use local Library Get it For Me service.

Official URL: http://dx.doi.org/10.1093/annonc/mds148

Request Changes to record.

Abstract

BACKGROUND:
Molecular circadian clocks can modify cancer chemotherapy effects, with a possible moderation according to sex differences. We investigated whether sex determine the optimal delivery schedule of chemotherapy for metastatic colorectal cancer.
PATIENTS AND METHODS:
A meta-analysis was performed using individual data from three international Phase III trials comparing 5-fluorouracil, leucovorin and oxaliplatin administered in chronomodulated (chronoFLO) or conventional (CONV) infusions. The data from 345 females and 497 males were updated at 9 years. The main end point was survival.
RESULTS:
Overall survival was improved in males on chronoFLO when compared with CONV (P = 0.009), with respective median values of 20.8 (95% CL, 18.7 to 22.9) and 17.5 months (16.1 to 18.8). Conversely, median survival was 16.6 months (13.9 to 19.3) on chronoFLO and 18.4 months (16.6 to 20.2) on CONV in females (P = 0.012). The sex versus schedule interaction was a strong predictive factor of optimal treatment schedule, with a hazard ratio of 1.59 (1.30 to 1.75) for overall survival (P = 0.002) in multivariate analysis.
CONCLUSIONS:
Males lived significantly longer on chronomodulated chemotherapy rather than on conventional chemotherapy. The current chronoFLO schedule deserves prospective assessment as a safe and more effective first-line treatment option than conventional delivery for male patients.

Item Type: Journal Article
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Science, Engineering and Medicine > Research Centres > Warwick Systems Biology Centre
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Circadian rhythms, Cancer—Chemotherapy--Sex differences , Metastasis , Rectum--Cancer , Colon (Anatomy)--Cancer
Journal or Publication Title: Annals of Oncology
Publisher: Oxford University Press
ISSN: 0923-7534
Official Date: December 2012
Dates:
DateEvent
December 2012Published
27 June 2012Available
Volume: Volume 23
Number: Number 12
Number of Pages: 7
Page Range: pp. 3110-3116
DOI: 10.1093/annonc/mds148
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Funder: Association pour la Recherche sur le Temps Biologique et la Chronothérapie (ARTBC International, Hôpital Universitaire Paul Brousse (Villejuif, France)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us